Cargando…
Systemic complement activation levels in Stargardt disease
PURPOSE: Preclinical research provides evidence for the complement system as a potential common pathway in Stargardt disease (STGD1) and age-related macular degeneration (AMD) leading to retinal pigment epithelium (RPE) loss. However, systemic complement activation has not yet been assessed in STGD1...
Autores principales: | Dhooge, Patty P. A., Runhart, Esmee H., Li, Catherina H. Z., de Kat Angelino, Corrie M., Hoyng, Carel B., van der Molen, Renate G., den Hollander, Anneke I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232401/ https://www.ncbi.nlm.nih.gov/pubmed/34170959 http://dx.doi.org/10.1371/journal.pone.0253716 |
Ejemplares similares
-
Correlation of Morphology and Function of Flecks Using Short-Wave Fundus Autofluorescence and Microperimetry in Patients With Stargardt Disease
por: Dhooge, Patty P. A., et al.
Publicado: (2021) -
Commentary on “Evidence of complement dysregulation in outer retina of Stargardt disease donor eyes”
por: Dhooge, Patty P.A., et al.
Publicado: (2021) -
Stargardt disease: monitoring incidence and diagnostic trends in the Netherlands using a nationwide disease registry
por: Runhart, Esmee H., et al.
Publicado: (2021) -
The STArgardt Remofuscin Treatment Trial (STARTT): design and baseline characteristics of enrolled Stargardt patients
por: Dhooge, Patty P.A., et al.
Publicado: (2022) -
Complement factor D haplodeficiency is associated with a reduced complement activation speed and diminished bacterial killing
por: Langereis, Jeroen D, et al.
Publicado: (2021)